Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility.
BACKGROUND
Protein kinase D (PKD) has been implicated in a wide range of cellular processes and pathological conditions including cancer. However, targeting PKD therapeutically and dissecting PKD-mediated cellular responses remains difficult due to lack of a potent and selective inhibitor. Previously, we identified a novel pan-PKD inhibitor, CID755673, with potency in the upper nanomolar range and high selectivity for PKD. In an effort to further enhance its selectivity and potency for potential in vivo application, small molecule analogs of CID755673 were generated by modifying both the core structure and side-chains.


RESULTS
After initial activity screening, five analogs with equal or greater potencies as CID755673 were chosen for further analysis: kb-NB142-70, kb-NB165-09, kb-NB165-31, kb-NB165-92, and kb-NB184-02. Our data showed that modifications to the aromatic core structure in particular significantly increased potency while retaining high specificity for PKD. When tested in prostate cancer cells, all compounds inhibited PMA-induced autophosphorylation of PKD1, with kb-NB142-70 being most active. Importantly, these analogs caused a dramatic arrest in cell proliferation accompanying elevated cytotoxicity when applied to prostate cancer cells. Cell migration and invasion were also inhibited by these analogs with varying potencies that correlated to their cellular activity.


CONCLUSIONS
Throughout the battery of experiments, the compounds kb-NB142-70 and kb-NB165-09 emerged as the most potent and specific analogs in vitro and in cells. These compounds are undergoing further testing for their effectiveness as pharmacological tools for dissecting PKD function and as potential anti-cancer agents in the treatment of prostate cancer.
Lavalle
Courtney R
CR
Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA. qjw1@pitt.edu.
Bravo-Altamirano
Karla
K
Giridhar
Karthik V
KV
Chen
Jun
J
Sharlow
Elizabeth
E
Lazo
John S
JS
Wipf
Peter
P
Wang
Q Jane
QJ
Science. 2002 Dec 6;298(5600):1912-34
12471243
Cancer Res. 2008 May 15;68(10):3844-53
18483269
Nat Cell Biol. 2005 Aug;7(8):779-81
16056272
Biochem Biophys Res Commun. 2010 Jan 1;391(1):63-8
19896460
Curr Biol. 2004 Jan 20;14(2):88-98
14738729
Mol Cell Biol. 2007 Oct;27(20):7248-65
17709384
Cancer Res. 2005 Jan 15;65(2):483-92
15695390
Trends Pharmacol Sci. 2006 Jun;27(6):317-23
16678913
J Biol Chem. 1998 Jan 2;273(1):410-6
9417097
Bioorg Med Chem. 2003 Sep 1;11(18):4133-41
12927875
Oncogene. 1997 Dec 11;15(24):2991-7
9416843
J Biol Chem. 2001 Feb 2;276(5):3310-8
11062248
J Cell Sci. 2004 Aug 1;117(Pt 17):3769-83
15252116
J Biol Chem. 2001 Aug 31;276(35):32606-15
11410586
Biochim Biophys Acta. 1999 May 6;1450(1):99-106
10231560
Cancer Res. 2009 Feb 1;69(3):1117-24
19141652
Cell Signal. 2007 Apr;19(4):867-79
17196367
Trends Cell Biol. 2007 Jan;17(1):13-8
17126550
Biochem Cell Biol. 2001;79(3):243-52
11467738
J Biol Chem. 1994 Feb 25;269(8):6140-8
8119958
Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8572-6
8078925
J Biol Chem. 2005 Sep 30;280(39):33262-9
16006559
J Cell Physiol. 2007 Jun;211(3):781-90
17226786
Biochem Biophys Res Commun. 2003 Jul 25;307(2):254-60
12859948
Mol Cell Biol. 2001 Apr;21(8):2755-66
11283255
J Biol Chem. 1999 Sep 10;274(37):26543-9
10473617
J Biol Chem. 2003 Jan 3;278(1):154-63
12407104
Oncogene. 1999 Aug 5;18(31):4440-9
10442635
J Biol Chem. 2008 May 9;283(19):12877-87
18337243
J Biol Chem. 1993 May 5;268(13):9194-7
8486620
Electrophoresis. 1999 Feb;20(2):382-90
10197446
EMBO J. 1996 Nov 15;15(22):6220-30
8947045
Oncogene. 2009 Aug 20;28(33):2925-39
19561645
Oncogene. 2003 Dec 4;22(55):8939-47
14654790
Cell Signal. 2008 Apr;20(4):581-9
18023328
Cancer Res. 2002 Mar 15;62(6):1632-40
11912133
J Med Chem. 1992 Mar 6;35(5):958-65
1372359
Nat Cell Biol. 2005 Sep;7(9):880-6
16100512
J Biol Chem. 2008 Nov 28;283(48):33516-26
18829454